Cargando…
Simultaneous inhibition of the estrogen receptor and 6-phosphofructo-2-kinase (PFKFB3) for the treatment of ER+ breast cancer
Autores principales: | Imbert-Fernandez, Yoannis, Telang, Sucheta, Chesney, Jason |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073006/ http://dx.doi.org/10.1186/2049-3002-2-S1-P29 |
Ejemplares similares
-
Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism
por: Klarer, Alden C, et al.
Publicado: (2014) -
Fructose-2,6-Bisphosphate synthesis by 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth
por: Chesney, Jason, et al.
Publicado: (2014) -
Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib
por: Telang, Sucheta, et al.
Publicado: (2014) -
Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor
por: Chesney, Jason, et al.
Publicado: (2015) -
The kinase domain of PFKFB4 is required to stimulate the glucose metabolism and growth of H460 xenografts
por: Clark, J, et al.
Publicado: (2014)